ESMO 2019 | PROMISE-meso: pembrolizumab vs. standard chemotherapy for mesothelioma

Sanjay Popat, PhD, MBBS, FRCP, Royal Marsden NHS Foundation Trust, London, UK, provides and update on the (ETOP 9-15) PROMISE-meso trial (NCT02991482 ), a multicentre randomized phase III trial comparing pembrolizumab versus standard chemotherapy for advanced pre-treated malignant pleural mesothelioma. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.